drugset / Trial / NCT02624557
Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To characterize the pharmacokinetics and safety of alpelisib in subjects with hepatic impairment compared to matched healthy control subjects.
Timeline
- Start
- 2015-12-21
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | 300 mg | — |
Indications
No indication recorded.